2-[2-[2-[Methyl-(2-nitrophenyl)sulfonylamino]ethylamino]-2-oxoethoxy]acetic acid | 1256269-50-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[2-[2-[Methyl-(2-nitrophenyl)sulfonylamino]ethylamino]-2-oxoethoxy]acetic acid
• CAS: 1256269-50-7
• 化学式: C₁₃H₁₇N₃O₈S
• 分子量: 375.359
• InChiKey: MPQLWQGXVKWCIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  167
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-[2-[2-[Methyl-(2-nitrophenyl)sulfonylamino]ethylamino]-2-oxoethoxy]acetic acid 、 N-{(S)-1-[3-(2-{2-[2-(2-Amino-acetylamino)-acetylamino]-acetylamino}-acetylamino)-phenyl]-2-pyrrolidin-1-yl-ethyl}-2-(3,4-dichloro-phenyl)-N-methyl-acetamide 在 1-羟基苯并三唑 、 N,N'-二环己基碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 26.25h， 生成
  参考文献：
  名称：

  A κ Opioid Pharmacophore Becomes a Spinally Selective κ-δ Agonist When Modified with a Basic Extender Arm

  摘要：

  We have explored the concept of a molecular extender arm attached to a kappa opioid agonist pharmacophore 3 (ICI-199,441) in an effort to potentially interact, with a complementary group on a neighboring opioid receptor. The containing a terminal amine group was lengthened incrementally from 11 1 up to 18 atoms. Increasing the number-of atoms in the arm produced virtually no change in the mouse intracerebroventricular (i.c.v.) antinociceptive potency In contrast, the intrathecal (i.t.) potency of 6 (KDA-16) with a 16 atom arm was dramatically increased, as reflected by its antinociceptive i.c.v./i.t. ED50 ratio of similar to 130. Further lengthening led to a decreased ED50 ratio. In vivo selective antagonist studies of KDA-16 revealed that kappa and delta opioid receptors were responsible for the greatly enhanced it potency Calcium release experiments in HEK-293 cells suggested that KDA-16 selectively activate kappa-delta heteromers. These data are consistent with the reported possible presence of heteromeric kappa-delta opioid receptors in mouse spinal cord but not in the brain. The use of a molecular extender arm may be useful for developing spinally selective analgesics.

  DOI：

  10.1021/ml1001294